Melane Sampson, Author at BioTuesdays

Developments

Athira Pharma extends open label extension AD studies with fosgonimeton

Athira Pharma (NASDAQ:ATHA) is extending the length of the current open label extension study for its Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s...

May 9, 2022

Markets

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

May 5, 2022

Developments

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

A key opinion leader highlighted the numerous technology advancements and clinical advantages of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO treatment of prostate diseases at a company hosted clinical education...

May 2, 2022

Developments

Limaca Medical receives FDA breakthrough device designation

The FDA granted closely held Limaca Medical of Israel breakthrough device designation for its Precision-GI endoscopic ultrasound biopsy product. The Precision-GI device is designed to obtain tumor tissue within or...

May 2, 2022

Developments

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...

May 2, 2022

Developments

Annovis Bio in pact with the National Institute on Aging

Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...

April 29, 2022

Developments

PharmaJet presents partner data on immunogenicity with needle-free systems

Closely held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...

April 27, 2022

Executive Moves

Sigyn Therapeutics names hepatology leader Dr. Donald Hillebrand to SAB

Dr. Donald Hillebrand Sigyn Therapeutics (OTC:SIGY) appointed Dr. Donald Hillebrand, M.D., to its scientific advisory board. Dr. Hillebrand is the associate medical director of liver transplantation at Saint...

April 26, 2022

Developments

FDA rejects Ampio Pharma proposal for modified filing of Ampion

The FDA rejected Ampio Pharmaceuticals’ (NYSE American:AMPE) proposed modified intent-to-treat (mITT) population as the primary analysis population for evaluating efficacy in the AP-013 trial, and the acceptability of...

April 21, 2022

Developments

LENZ Therapeutics and JIXING in exclusive greater China license agreement

Closely held LENZ Therapeutics entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment...

April 13, 2022

Author - Melane Sampson

Athira Pharma extends open label extension AD studies with fosgonimeton

SVB cuts Aligos to market perform; PT to $3 from $7

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

Limaca Medical receives FDA breakthrough device designation

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

Annovis Bio in pact with the National Institute on Aging

PharmaJet presents partner data on immunogenicity with needle-free systems

Sigyn Therapeutics names hepatology leader Dr. Donald Hillebrand to SAB

FDA rejects Ampio Pharma proposal for modified filing of Ampion

LENZ Therapeutics and JIXING in exclusive greater China license agreement

Subscribe